Pulmicort Aerosol, Powder
NDC Package 85612-010-01
Package Information
Pulmicort (budesonide) aerosols is the use of PULMICORT FLEXHALER is contraindicated in the following conditions:Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.Severe hypersensitivity to milk proteins or any ingredients of PULMICORT FLEXHALER [see Warnings and Precautions (5.3), Description (11)]. This formulation utilizes a aerosol, powder delivery system. Marketed by Rubicon Holdings Inc., this product is identified by NDC 85612-010 and is authorized under FDA application NDA021949.
Identification & Billing
- RxCUI: 966522 - budesonide 180 MCG/INHAL Dry Powder Inhaler, 120 ACTUAT
- RxCUI: 966522 - 120 ACTUAT budesonide 0.18 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 966522 - budesonide 0.18 MG/ACTUAT (0.16 MG/ACTUAT from the mouthpiece) Dry Powder Inhaler, 120 ACTUAT
- RxCUI: 966522 - budesonide 180 MCG/ACTUAT Dry Powder Inhaler, 120 ACTUATS
- RxCUI: 966524 - Pulmicort Flexhaler 180 MCG/INHAL Dry Powder Inhaler, 120 ACTUAT
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 85612 - Rubicon Holdings Inc.
- 85612-010 - Pulmicort
- 85612-010-01 - 1 INHALER in 1 CARTON / 60 AEROSOL, POWDER in 1 INHALER
- 85612-010 - Pulmicort
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 85612-010-01 identifies a specific commercial package of 1 inhaler in 1 carton / 60 aerosol, powder in 1 inhaler of Pulmicort Flexhaler, a human prescription drug labeled by Rubicon Holdings Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This aerosol, powder is formulated for respiratory (inhalation) use and contains budesonide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rubicon Holdings Inc. on August 14, 2025. The current certification is valid through December 31, 2027.
How is this Rubicon Holdings Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 85612001001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.